Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV
Julia A Aepfelbacher, Julia Balmaceda, Julia Purdy, Aviva Mattingly, Kirsten Zambell, Karyn Hawkins, Cheryl Chairez, Kara Anne Curl, Nicola Dee, Colleen Hadigan, Julia A Aepfelbacher, Julia Balmaceda, Julia Purdy, Aviva Mattingly, Kirsten Zambell, Karyn Hawkins, Cheryl Chairez, Kara Anne Curl, Nicola Dee, Colleen Hadigan
Abstract
Little is known about the effects of lifelong human immunodeficiency virus (HIV) or antiretroviral therapy on hepatic steatosis and fibrosis. Using transient elastography, we evaluated 46 young adults with lifelong HIV and 20 matched HIV-negative controls. Steatosis was present in 33% of persons with HIV and only 10% of controls (P = .04). Hepatic fibrosis scores were not elevated and did not differ between groups. Metabolic parameters, particularly increased waist circumference, and not HIV-specific factors, were significantly associated with steatosis. While this finding should be examined in larger cohorts, modifiable metabolic disturbances may be important targets to optimize liver health in this population.
Trial registration: ClinicalTrials.gov NCT01656564.
Keywords: AIDS; HIV; hepatic steatosis; nonalcoholic fatty liver disease; young adults.
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Source: PubMed